MASH Research • Target Product Profile • Pharmaceutical Strategy

MASH Target Product Profile Research Developing Differentiated Product Strategies

Turning clinical evidence and stakeholder insights into strategic MASH product development decisions.

MASH Target Product Profile MASH Market Research Product Differentiation
The opportunity

Navigating an Increasingly Competitive MASH Landscape

The MASH treatment landscape is evolving rapidly. With two FDA-approved therapies, expanding clinical programmes and multiple investigational mechanisms, pharmaceutical companies face increasing pressure to establish meaningful product differentiation.

Clinical efficacy alone may not define competitive advantage. Physician preferences, patient expectations, safety and tolerability, treatment convenience and payer requirements all influence the potential positioning of an emerging therapy.

This makes evidence-driven MASH Target Product Profile (TPP) development an important component of pharmaceutical research and development. Through structured MASH Market Research, pharmaceutical companies can better understand stakeholder expectations, evaluate unmet clinical needs and identify opportunities to strengthen the positioning of emerging therapies.

At SPER Market Research, we support pharmaceutical and biotechnology companies with specialised MASH Primary Market Research to develop, refine and validate differentiated MASH TPPs. Our research approach combines clinical evidence, physician perspectives and market insights to support informed product development decisions.

Our MASH TPP Research Solutions

We provide four integrated research solutions to support MASH TPP Development and commercial decision-making.

01

Unmet Need & Competitive Positioning

Understand clinical and commercial white spaces through specialist stakeholder research and MASH Competitive Landscape assessment.

  • Hepatologist and endocrinologist interviews.
  • Benchmarking against approved and emerging therapies.
  • Assessment of unmet clinical needs.
  • Identification of differentiation opportunities.

Deliverable: Unmet-need assessment and competitive positioning framework.

02

TPP Attribute Prioritisation

Identify which product attributes matter most to physicians, patients and other stakeholders to support effective Pharmaceutical TPP Development.

  • Fibrosis improvement and MASH resolution.
  • Weight-loss and metabolic benefits.
  • Safety and tolerability.
  • Dosing frequency and administration preferences.
  • Conjoint Analysis and MaxDiff studies.

These methodologies help assess stakeholder preferences, evaluate attribute trade-offs and identify opportunities for meaningful MASH Product Differentiation.

Deliverable: Attribute importance scores, preference shares and trade-off maps.

03

Payer & Market Access Research

Understand reimbursement expectations and market-specific evidence requirements through structured MASH Market Access Research.

  • Payer and HTA stakeholder interviews.
  • Willingness-to-reimburse assessment.
  • Comparative clinical value research.
  • Market access and evidence requirement assessment.

Deliverable: Payer insights and market-specific access evidence.

04

Competitive Intelligence

Monitor the evolving MASH pipeline and assess opportunities for asset differentiation through comprehensive MASH Competitive Landscape research.

  • Mechanism-of-action benchmarking.
  • Clinical trial and milestone tracking.
  • Efficacy and safety evidence assessment.
  • Competitive positioning and KOL mapping.

Deliverable: MASH competitive landscape and asset differentiation reports.

Key target product profile attributes for MASH therapies
Illustrative view of the product attributes considered during MASH TPP prioritisation.

Integrated Research Across the MASH Stakeholder Ecosystem

Our research framework brings together perspectives from multiple stakeholders to support MASH TPP research for pharmaceutical companies.

  • Hepatologists: Clinical expectations and treatment preferences.
  • Endocrinologists: Metabolic management and treatment selection.
  • Primary Care Physicians: Patient identification and referral pathways.
  • Payers and HTA Stakeholders: Reimbursement expectations and evidence requirements.
  • Patients: Treatment preferences, convenience and treatment burden.

By integrating these perspectives, SPER helps clients understand the attributes that influence product evaluation and potential market acceptance. This stakeholder-led approach also strengthens the evidence base required for effective TPP development and product positioning.

From Unmet Need to a Stakeholder-Validated TPP

Our five-stage research framework supports the complete TPP development journey:

01 / Unmet Need

Identify clinical and commercial opportunities.

02 / Draft TPP

Define relevant product attributes and stakeholder expectations.

03 / Target TPP

Assess desired product performance and attribute trade-offs.

04 / Refine & Defend

Evaluate competitive differentiation and product positioning.

05 / Validated TPP

Consolidate stakeholder evidence to support development and commercial decisions.

Each stage can be commissioned independently or as part of a continuous research programme. Our approach to MASH TPP Development helps pharmaceutical and biotechnology companies align product attributes with clinical expectations, stakeholder preferences and evolving market requirements.

Research Methodologies and Execution

SPER integrates qualitative and quantitative methodologies to deliver actionable insights through Primary Market Research for MASH Therapies, including:

  • In-depth interviews and focus groups.
  • Conjoint Analysis and MaxDiff.
  • CATI, CAPI and CAWI.
  • Patient journey mapping.
  • Decision modelling and MCDA.
  • Digital and mobile research.
  • Competitive intelligence and secondary research.

Our structured engagement process covers project scoping, respondent feasibility, research design, recruitment, fieldwork monitoring and quality-checked deliverables.

Typical engagement timelines are 4–10 weeks, depending on research scope, geography, sample requirements and respondent availability.

Partner with SPER Market Research

Whether you are evaluating an emerging MASH asset, developing an early-stage TPP, refining a Phase 2/3 product profile or assessing competitive differentiation, understanding stakeholder expectations is essential.

SPER Market Research helps translate primary research into actionable insights for pharmaceutical product development and commercial strategy. Our specialised MASH Market Research capabilities support informed decisions across unmet needs assessment, TPP attribute prioritisation, competitive intelligence and payer research.

Let's discuss your MASH TPP research requirements.

Explore MASH Research

SPER Market Research – Primary Market Research. Strategic Decisions.

Thought Leadership

Trusted by Industry Leaders

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-Danaher
SPER-AandM
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken
HIPPA Compliant
GDPR Certified
ISO 27001
Peer Reviewed
Get Started Today

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.

No Credit Card Required
15-Minute Demo
Expert Guidance